Common Contracts

Licensing and option agreement for iSONEP for wet age-related macular degeneration

Licensing Agreement • February 2nd, 2022 • New York

• Contract Type
  Licensing Agreement
• Filed
  February 2nd, 2022
• Jurisdiction
  New York

Lpath has entered into an agreement providing Pfizer with an exclusive option for a worldwide license to develop and commercialize iSONEPTM for the treatment of wet age-related macular degeneration (wet AMD) and other ophthalmology disorders.